Limitations of Chromogranin A in clinical practice

Vincenzo Marotta, Vincenzo Nuzzo, Teresa Ferrara, Alfonso Zuccoli, Milena Masone, Lorenzo Nocerino, Michela Del Prete, Francesca Marciello, Valeria Ramundo, Gaetano Lombardi, Mario Vitale, Annamaria Colao, Antongiulio Faggiano

Research output: Contribution to journalArticle

Abstract

Context: Usefulness of circulating Chromogranin A (CgA) for the diagnosis of neuroendocrine tumors (NEN) is controversial. The aim of the present study was to assess the actual role of this marker as diagnostic tool. Methods: Serum blood samples were obtained from 42 subjects affected with NEN, 120 subjects affected with non-endocrine neoplasias (non-NEN) and 100 non-neoplastic subjects affected with benign nodular goitre (NNG). Determination of CgA was performed by means of immunoradiometric assay. Results: The CgA levels among NEN-patients were not significantly different from NNG and non-NEN subjects. The Receiver operating characteristic (ROC) curves analysis failed to identify a feasible cut-off value for the differential diagnosis between NEN and the other conditions. Conclusion: Serum CgA is not helpful for the first-line diagnosis of NEN.

Original languageEnglish
Pages (from-to)186-191
Number of pages6
JournalBiomarkers
Volume17
Issue number2
DOIs
Publication statusPublished - Mar 2012

    Fingerprint

Keywords

  • Chromogranin A
  • Chronic atrophic gastritis
  • False positive marker
  • Neuroendocrine tumor
  • Proton pump inhibitors

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Health, Toxicology and Mutagenesis

Cite this

Marotta, V., Nuzzo, V., Ferrara, T., Zuccoli, A., Masone, M., Nocerino, L., Del Prete, M., Marciello, F., Ramundo, V., Lombardi, G., Vitale, M., Colao, A., & Faggiano, A. (2012). Limitations of Chromogranin A in clinical practice. Biomarkers, 17(2), 186-191. https://doi.org/10.3109/1354750X.2012.654511